AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.97
−0.87%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.66x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 10.80x
- Price / sales
- 1.23x
- Price / cash flow
- 6.50x
Enterprise value
- Enterprise value
- $168.5M
- EV / sales
- 0.77x
- EV / EBITDA
- -9.36x
- EV / EBIT
- -11.14x
- Market cap
- $270.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026